Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;65(3):403-419.
doi: 10.1007/s12016-023-08975-z. Epub 2023 Dec 29.

Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis

Nicoletta Luciano  1 , Elisa Barone  1   2 , Suraj Timilsina  3 , M Eric Gershwin  3 , Carlo Selmi  4   5
Affiliations
Review

Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis

Nicoletta Luciano et al. Clin Rev Allergy Immunol. 2023 Dec.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by an increased risk of cardiovascular events, due to the complex interplay between traditional and disease-related risk factors. Chronic inflammation and persistent disease activity are the key determinants of this risk, but despite great improvement in the disease management and prognosis, cardiovascular events are still the main cause of morbidity and mortality in RA cohorts1. In the last decades, the advent of new biological and targeted-synthetic DMARDs was accompanied by an improvement in disease activity control, but the role of each class of drugs on CVD risk is still a matter a debate. Since their approval for RA treatment, tumor necrosis factor alpha (TNFα) inhibitors have been widely investigated to better understand their effects on cardiovascular outcomes. The hypothesis that the reduction of chronic inflammation with any treatment may reduce the cardiovascular risk has been recently confuted by the direct comparison of TNFα-inhibitors and JAK inhibitors in patients with RA and coexisting risk factors for cardiovascular disease. The aim of this literature review is to add to the available evidence to analyze the relationship between TNFα-inhibitors and CVD risk in patients with RA and also provide some clinical scenarios to better explain the treatment dilemmas. In particular, while data on major cardiovascular events and thromboembolism seem consistent with an inflammation-mediated benefit with TNFα-inhibitors, there remain concerns about the use of this class of bDMARDs in patients with chronic heart failure.

Keywords: Biologics; Cardiovascular risk; Chronic heart failure; Rheumatoid arthritis; Tumor necrosis factor.

PubMed Disclaimer

References

    1. Løgstrup BB, Ellingsen T, Pedersen AB et al (2021) Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population. Rheumatology 60(3):1400–1409. https://doi.org/10.1093/RHEUMATOLOGY/KEAA374 - DOI - PubMed
    1. van der Woude D, van der Helm-van Mil AHM (2018) Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol 32(2):174–187. https://doi.org/10.1016/J.BERH.2018.10.005 - DOI - PubMed
    1. Conforti A, Di Cola I, Pavlych V et al (2021) Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev 20(2):102735. https://doi.org/10.1016/J.AUTREV.2020.102735 - DOI - PubMed
    1. Liao KP (2017) Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med 27(2):136–140. https://doi.org/10.1016/J.TCM.2016.07.006 - DOI - PubMed
    1. Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52(2):402–411. https://doi.org/10.1002/ART.20853 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources